Technical Data
Protein C Inhibitor (PCI)
Protein C Inhibitor (PCI), also known as Plasminogen Activator Inhibitor 3 (PAI3), is a member of the SERPIN family of proteinase inhibitors. It is produced in the liver as a single chain glycoprotein (mass of 57kD) and circulates in plasma at a concentration of 5ug/ml (~90nM). PCI is also found in urine in lower concentrations of 250ng/ml (~0.4nM).
PCI is the primary inhibitor of activated Protein C (APC) in plasma but demonstrates a relatively broad specificity, also inhibiting thrombin, FXa, FXIa, kallikrein, tPA, urokinase, prostate specific antigen, acrosin, chymotrypsin and trypsin. The preferred enzyme target for PCI appears to be thrombin and this interaction is increased by more than 100 fold in the presence of thrombomodulin. Like ATIII and HCII, the inhibitory activity of PCI towards some of these enzymes is stimulated by high concentrations of heparin (5U/ml) which can accelerate the rate of inactivation as much as 50 fold. Enzyme inhibition by PCI occurs through proteolytic cleavage at Arg354-Ser355 and subsequent rapid formation of a stable, inactive 1:1 enzyme-PCI complex. Interaction with APC results in an SDS-stable APC-PCI complex of 102kD.

Suitable for use in ELISA and Immunoelectrophoresis. Other applications not tested.

Recommended Dilutions:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
500ug-20CBlue IceHumanGoat
Human Protein C Inhibitor (PCI) purified from plasma
Purified by immunoaffinity chromatography.
Supplied as a liquid in 10mM HEPES, pH 7.4, 150mM sodium chloride, 50% glycerol.
Recognizes human Protein C Inhibitor (PCI).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Suzuki K; Protein C Inhibitor; Methods in Enzymology 222, pp 385- 399, 1993. 2. Cooper ST, Whinna HC, Jackson TP, Boyd JM, Church FC; Biochemistry: 34, pp. 12991-12997, 1995. 3. Heeb MJ, Espana F, Geiger M, Collen D, Stump DC, Griffin JH; 3; JBC:262, pp 15813- 15816, 1987. 4. Rezaie AR, Copper ST, Church FC, Esmon CT; JBC: 270, pp 25336-25339, 1995.